Semaglutide Fails to Improve Executive Function in Depression but Shows Cognitive Signals
A 16-week randomized, double-blind trial of oral semaglutide in 72 adults with major depressive disorder found no improvement in executive function vs placebo. However, secondary analyses showed semaglutide improved global cognition and produced clinically significant weight loss, suggesting potential but unclear neuropsychiatric benefit.